Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its OpenAlex record.

Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.

Shinsaku Imashuku, Shigeyoshi Hibi, Toshio Ohara, Asayuki Iwai, Masahiro Sako, Masahiko Katô, Hirokazu Arakawa, Manabu Sotomatsu, Satoshi Kataoka, Keiko Asami, Daiichiro Hasegawa, Yoshiyuki Kosaka, Kimihiko Sano, N Igarashi, K Maruhashi, Ryouji Ichimi, H Kawasaki, Naoko Maeda, Akihiko Tanizawa, Koji Arai, Takanori Abe, Hiroaki Hisakawa, Hidemasa Miyashita, Jan‐Inge Henter · 1999 · PubMed

Abstract

The familial form of hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder. Although the prognosis for Epstein-Barr virus-associated HLH (EBV-HLH) remains uncertain, numerous reports indicate that it can also be fatal in a substantial proportion of cases. We therefore assessed the potential of immunochemotherapy with a core combination of steroids and etoposide to control EBV-HLH in 17 infants and children who met stringent diagnostic criteria for this reactive disorder of the mononuclear phagocyte system. Treatment of life-threatening emergencies was left to the discretion of participating investigators and typically included either intravenous Ig or cyclosporin A (CSA). Five patients (29%) entered complete remission during the induction phase (1 to 2 months), whereas 10 others (57%) required additional treatment to achieve this status. In 2 cases, immunochemotherapy was ineffective, prompting allogeneic bone marrow transplantation. Severe but reversible myelosuppression was a common finding; adverse late sequelae were limited to epileptic activity in one child and chronic EBV infection in 2 others. Fourteen of the 17 patients treated with immunochemotherapy have maintained their complete responses for 4+ to 39+ months (median, 15+ months), suggesting a low probability of disease recurrence. These results provide a new perspective on EBV-HLH, showing effective control (and perhaps cure) of the majority of EBV-HLH cases without bone marrow transplantation, using steroids and etoposide, with or without immunomodulatory agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1182/blood.v93.6.1869.406a31_1869_1874

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 193

Metadata

Authors
Imashuku, S., Hibi, S., Ohara, T., Iwai, A., Sako, M., Katô, M., Arakawa, H., Sotomatsu, M., Kataoka, S., Asami, K., Hasegawa, D., Kosaka, Y., Sano, K., Igarashi, N., Maruhashi, K., Ichimi, R., Kawasaki, H., Maeda, N., Tanizawa, A., Arai, K., Abe, T., Hisakawa, H., Miyashita, H., & Henter, J.
Venue
PubMed
Publisher
National Institutes of Health
Published
1999-03-15
Volume
93
Issue
6
Pages
1869-74
OpenAlex
W2162777258
Cited by
193
References
0
FWCI
6.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. https://app.cochat.ai/papers/10.1182/blood.v93.6.1869.406a31_1869_1874
The paper
Imashuku, S., Hibi, S., Ohara, T., Iwai, A., Sako, M., Katô, M., Arakawa, H., Sotomatsu, M., Kataoka, S., Asami, K., Hasegawa, D., Kosaka, Y., Sano, K., Igarashi, N., Maruhashi, K., Ichimi, R., Kawasaki, H., Maeda, N., Tanizawa, A., . . . Henter, J. (1999). Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. PubMed. https://doi.org/10.1182/blood.v93.6.1869.406a31_1869_1874

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.